-
2023-509861-19-00
4
Diffuse large B-cell lymphoma (DLBCL)
-
2024-513724-42-00
10
Medulloblastoma
-
2024-514682-19-00
5
Resected pancreatic ductal adenocarcinoma
-
2024-516115-24-00
9
High risk relapsed neuroblastoma (relapsed or progressed after being d
-
2024-516734-35-00
5
triple-negative early breast cancer
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517295-37-00
5
low and intermediate risk neuroblastoma
-
2024-517937-41-00
4
extensive stage small cell lung cancer (SCLC)
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2024-519504-27-00
5
Relapsed Refractory Multiple Myeloma
-
2024-519786-22-01
9
metastatic non-small cell lung cancer (NSCLC)
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-521037-86-00
5
Immune system diseases
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-523576-23-00
5
Unresectable Stage III non-small cell lung cancer without progression
-
2025-523630-59-00
9
colon carcinoma metastases
-
2025-523735-19-00
5
Metastatic Microsatellite Stable Colorectal Cancer
-
2025-523947-36-00
4
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap
-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524468-40-00
3
chronic Graft-versus-Host-Disease (cGvHD)
-
2026-525640-14-00
6
Candidemia
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia